Lymphoproliferative Disorders
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Subtype terms (21)
More specific conditions that are subtypes of Lymphoproliferative Disorders in the MeSH hierarchy.
- Agammaglobulinemia
29 drugs (27 approved, 2 experimental)
- Autoimmune Lymphoproliferative Syndrome
7 drugs (5 approved, 2 experimental)
- Castleman Disease
25 drugs (22 approved, 3 experimental)
- Granuloma
46 drugs (35 approved, 11 experimental)
- Heavy Chain Disease
- Immunoblastic Lymphadenopathy
1 drug approved
- Immunoglobulin Light-chain Amyloidosis
59 drugs (43 approved, 16 experimental)
- Immunoproliferative Small Intestinal Disease
- Infectious Mononucleosis
10 drugs (4 approved, 6 experimental)
- Leukemia, Hairy Cell
93 drugs (64 approved, 29 experimental)
- Leukemia, Lymphoid
167 drugs (93 approved, 74 experimental)
- Lymphangiomyoma
1 drug approved
- Lymphoma
1111 drugs (436 approved, 675 experimental)
- Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)
- Marek Disease
- Multiple Myeloma
992 drugs (335 approved, 657 experimental)
- Plasmacytoma
92 drugs (60 approved, 32 experimental)
- Sarcoidosis
57 drugs (43 approved, 14 experimental)
- Sezary Syndrome
125 drugs (81 approved, 44 experimental)
- Tumor Lysis Syndrome
4 drugs approved
- Waldenstrom Macroglobulinemia
181 drugs (98 approved, 83 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (20)
Phase 2 trials (62)
- methylprednisolone
- acalabrutinib
- allogeneic natural killer cells
- autologous immunoglobulin idiotype-klh conjugate vaccine
- urea
- bendamustine
- brentuximab vedotin
- lenalidomide
- prednisone
- obinutuzumab
- ethanol
- gemcitabine
- tacrolimus
- naltrexone
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- hemopoietic stem cell
- hydroxyurea
- interferon alpha-2a
- nivolumab
- leucovorin
- vincristine
- pentostatin
- sodium phenylbutyrate
- allogeneic hematopoietic stem cells
- immune globulin (human)
- sirolimus
- cyclosporine
- mycophenolate
- leflunomide
- sulfamethoxazole
- +32 more
Phase 1 trials (30)
- autologous ebv specific cytotoxic t lymphocytes
- clofarabine
- eb-vst cells
- icaspase9-transduced t cells
- Imetelstat
- ganciclovir
- kx2-391
- beta-glucans
- pemetrexed
- phenethyl isothiocyanate
- siplizumab
- bevacizumab
- vandetanib
- dimethylarsinous glutathione
- autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine
- ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
- mabel ctls
- sulfadoxine
- ebna1-specific cytotoxic t-lymphocytes
- barf1-specific cytotoxic t-lymphocytes
- pyrimethamine
- sivifene
- motesanib
- phosphate
- Brexucabtagene autoleucel
- allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells
- qs21
- EBV Specific T-Lymphocytes
- oricar-017
- kln-1010
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (17)
- AB2 Bio Ltd.
- Atara Biotherapeutics
- Chugai
- National Cancer Institute (NCI)
- University of Pennsylvania
- Harvard University
- Gruppo Italiano Trapianto di Midollo Osseo
- Stanford University
- Sundsvall Hospital
- University of Edinburgh
- University of Michigan
- Mayo Clinic
- University of California, Los Angeles
- Department of Defense
- University of Minnesota
- Ludwig Maximilians University
- WiSP GmbH
Organization Involved with Phase 2 Indications (48)
- Seattle Genetics
- Celgene
- Millennium Pharmaceuticals
- Genentech
- Juno Therapeutics, Inc.
- Fondazione Progetto Ematologia
- National Heart, Lung, and Blood Institute (NHLBI)
- Maisonneuve-Rosemont Hospital
- AIDS Malignancy Consortium
- Baylor University
- Boston University
- Case Western Reserve University
- Cornell University
- University of Washington
- Northside Hospital, Inc.
- Northwestern University
- Ohio State University
- Rutgers University
- Thomas Jefferson University
- University of Florida
- University of Medicine and Dentistry of New Jersey
- University of Miami
- University of Rochester
- University of Southern California
- University of Toronto
- Wayne State University
- Fudan University
- University of California, San Diego
- University of California, San Francisco
- University of Chicago
- +18 more
Organization Involved with Phase 1 Indications (21)
- Morphotek
- MedImmune
- Arno Therapeutics
- DEKK-TEC, Inc.
- Geron Corporation
- bluebird bio
- Ziopharm
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Cancer Research UK
- University of London
- Johns Hopkins University
- New York Medical College
- Ohio University
- University of Birmingham
- Fujian Medical University
- University of Colorado, Denver
- University of Utah
- University of Wisconsin
- University of Alabama, Birmingham
- Children's National Medical Center
Organization Involved with Other Experimental Indications (4)